Willem Lybaert retweeted
🔊🔊 Daraxonrasib approved in EU !! New hope for #pancreaticcancer patients!! @_SEOM @VHIO @vallhebron @GrupoTTD @GEPAC_ @Alipanc1 @RevMedicines
revmed.com/media/
Willem Lybaert retweeted
Daraxonrasib is now approved in the second line and beyond in metastatic #PancreaticCancer in the European Union. Good news for patients across the pond! @RevMedicines @KRASKickers
revmed.com/media/news/13736/…
Willem Lybaert retweeted
📢November is #LungCancerAwarenessMonth.
Let’s talk about lung NETs: Persistent cough and wheezing can be symptoms that are often mistaken for more common conditions.
✅We help clinicians to make early diagnosis with a #NETInfo in 14 languages: incalliance.org/net-info-pac…
#LetsTalkAboutNETs
Willem Lybaert retweeted
🚨 IVONESCIMAB: PFS WIN, OS MISS — FDA SAYS NO!
HARMONi Phase III | FDA Complete Response Letter (CRL)
🔹 Population: EGFR-mutated advanced nonsquamous NSCLC after 3rd-generation EGFR TKI.
🔹 Design: Ivonescimab + platinum chemotherapy vs placebo + chemotherapy.
🔹 PFS: Statistically significant improvement ✅
🔹 OS: Not statistically significant ❌
Post-hoc HR 0.76 — favorable trend, no proven OS benefit.
🔹 FDA verdict: Benefit–risk evidence insufficient for approval as submitted.
🔹 Regulatory status: 🇺🇸 Not FDA-approved | 🇨🇳 Initially approved May 2024.
🔹 What's next? HARMONi-3, HARMONi-7 and broader clinical development continue.
🎯 TAKE-HOME: PFS success ≠ OS success ≠ FDA approval.
📚 Reference: Summit Therapeutics | November 15, 2026 | HARMONi Phase III | FDA CRL announcement.
#Ivonescimab #HARMONi #NSCLC #LungCancer #EGFR #FDA #Oncology #ClinicalTrials #MVOnco
@OncoDaily @OncoAlert @larvol
Willem Lybaert retweeted
De regering zal niet alleen vallen door @vooruit_nu, maar door het totale gebrek aan realiteitszin over het uitgavenniveau, de toestand van de economie en de ramp van nieuwe verkiezingen en miljarden extra lasten die dat meebrengt door rentebetalingen, verdere uitgavenontsporingen en wantrouwen om nog te investeren in dit land.
Willem Lybaert retweeted
Are you like me, feeling intimidated by and unsure about the management of patient with mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) of gastroenteropancreatic origin?
If so, this is a review article you will want to read. Excellent @ENETS_ORG position statement, led by @FRANCES88189587 and a panel of folks who know their stuff.
Check it out!
onlinelibrary.wiley.com/doi/…
Willem Lybaert retweeted
Siamo cresciuti negli ultimi 50-60 anni con una sorta di "imposizione sociale" del devi avere per essere accettato.
Devi avere una laurea, altrimenti non vali
Devi avere la fidanzatina da adolescente altrimenti sei uno sfigato
Devi sposarti e avere figli, altrimenti non sei visto di buon occhio
Devi comprarti casa
Devi avere un lavoro fisso
Devi essere in forma
Devi apparire sempre vincente
Con l'avvento di internet e dei social media, tutti quei devi non solo si sono rafforzati, ma si è creata una sorta di corsa a ostacoli, dove vince chi raggiunge tutti questi obiettivi nel minor tempo possibile.
Questo ha generato dei mostri.
I nostri ragazzi vivono una pressione tale che devono raggiungere questi obiettivi nel più breve tempo possibile. In questo modo o vanno in tilt o credono che questi "devi avere" gli spettano di diritto e diventano violenti.
I più grandi scoprono che nella maggior parte dei casi è impossibile avere tutto e vanno in crisi
Poi è arrivata l'IA che molto probabilmente sostituirà molte persone nei luoghi di lavoro, creando ancora più ansia e crisi sociale.
Ma allora la mia domanda è la seguente:
Abbiamo davvero bisogno di tutti questi "devi avere"?
Devi avere per forza una laurea per essere considerato una persona valida?
Devi per forza sposarti e avere figli per essere accettato socialmente?
Devi per forza avere un lavoro fisso dove fai la stessa mansione per 40 anni per generare una fonte di reddito?
Devi per forza apparire sempre vincente e mai "umano" per essere accettato dagli altri?
E se invece ci fermassimo un secondo a pensare e a iniziare a considerare che niente ci è dovuto? Che ognuno sceglie la sua strada seguendo le proprie inclinazioni senza per forza essere inglobato in un'etichetta sociale, che avere un lavoro o comprarsi una casa è 100 volte più difficile rispetto a 40 anni fa perché la competizione è aumentata e i prezzi sono saliti in maniera incontrollata?
Se ci fermassimo a pensare che invece di cercare di apparire sempre vincenti seguendo delle etichette predefinite, sarebbe meglio essere più umili e mostrare quello che veramente siamo, con pregi e difetti?
Se ci fermassimo a pensare che su 100 adolescenti è praticamente impossibile che tutti e 100 diventino super stars, ma che ci arrivano solo quelli talentuosi?
Se ci fermassimo a pensare che cercare di far diventare per forza una persona quello che non vuole o non può essere utilizzando ogni mezzo (pressione psicologica, raccomandazioni etc) crea un danno serio a quella persona e agli altri?
Se ci fermassimo a pensare che se gli adolescenti sono violenti e inseguono influencers sui social media come persone da imitare forse qualcosa che non va esiste?
Se ci fermassimo a pensare che forse tutti questi obiettivi che ci poniamo ci sono imposti da etichette sociali e che ognuno ha un suo valore a prescindere da quanto guadagna, quante case ha, se lavora o meno, etc?
Se ci fermassimo a pensare che quelli che giovano di tutti quei "devi avere" sono pochi, mentre la maggior parte delle persone annaspa e non li avrà mai tutti insieme?
Ha senso continuare a imporre degli obiettivi che la maggior parte delle persone non raggiungerà mai per la follia collettiva che uno vale uno e tutti possono diventare super star in qualsiasi campo, senza contare il talento o il merito?
Ha senso vivere in un'isteria sempre più dilagante, dove molte persone poi si accorgono, tardi, che tutta questa energia sprecata fin da adolescenti era dedicata ad inseguire un'illusione imposta da genitori, amici etc?
Se ogni tanto ci sedessimo e pensassimo davvero, "ma io dove posso realmente arrivare", considerando realmente il proprio talento e i propri limiti, non vivremmo, forse, una vita più consona al livello di ognuno?
Willem Lybaert retweeted
Few considerations regarding CAMORAL (now in @JAMAOnc) neoadjuvant chemoIO for resectable #hncsm:
1) surgery not response adapted
2) not meant to convert borderline resectable to resectable disease. 6% on both arms clinical stage 4B (presumably on basis of large neck nodes)?
3) surgery window up to 6 weeks post chemoIO. In KN-689 this was ~3 weeks. With NPC induction chemo prior to definitive chemoRT, the interval is 3-4 weeks. 6 weeks may be too permissive a benchmark for future real world translation of this approach. 17% delayed past 6 weeks post-chemoIO reportedly due to Covid.
4) per supplement, progression during neoadjuvant phase was NOT counted as progression event as long as could proceed to surgery. Similar to KN-689. Underscores importance of not selecting borderline inoperable patients for these paradigms and closely monitoring during neoadjuvant phase.
5) radiation #radonc omitted for pCR. I am curious to know what percentage/number of the failures were among these patients which is critical. While there is enthusiasm about de-escalation implications for adjuvant therapy as a result of neoadjuvant approaches, radiation omission should not be considered off trial IMO. KN-689 did NOT included omission of RT; while tempting if pathologic stage drops below stage 3 and margins adequate, don’t have pathologic sufficient response rates with IO alone and presently insufficient evidence. Zinner PMID 41385730 chemoIO trial has shown high rates of recurrence (5/8 pts) where radiation was not completed among patients with mPR/pCR. Perhaps pCR is a better selected cohort for exploring an omission approach on study, but would not consider this off trial. Stage 3-4 HPV negative disease is not the same major de-escalation scenario as early-stage HPV+ OPC: surgical salvage is more morbid and functionally impactful at the primary site and “definitive” RT has suboptimal outcomes.
6) MPR of 48% lower than on other chemoIO regimens where closer to 60ish percent. Is Carbo paclitaxel less cytoreductive than cisplatin from path response perspective, in absence of synergy with something like radiation? I am not sure the IO choice is the reason for the lower path response here and again numbers somewhat small in CAMORAL.
7) Benefit like in KN-689 seems to be in distant control. This is probably the early priming of an intact immune system. I am not sure how much the adjuvant IO does in light of what we know about IO efficacy across disease sites after irradiation of cervical nodes, let alone after both dissection and radiation. NIVOPOST-OP adjuvant IO reportedly improved locoregional and not distant control, but 45% were pathologically stage 4B so perhaps already too advanced to mitigate distant failure risk (assuming comprehensive staging upfront to exclude early Mets) and the outcomes were not positive upon BICR.
Exciting times as we find better strategies for treating stage 3-4 resectable disease where we need to do better!
For patients with resectable locally advanced #HeadAndNeckSquamousCellCarcinoma, perioperative camrelizumab plus chemotherapy improved 2-year event-free survival vs standard surgery-based treatment. ja.ma/4kaMIR0
Willem Lybaert retweeted
RINGSIDE Phase II | Daily Varegacestat: Deeper Shrinkage in Desmoid Tumors!
💊 Study: Randomized, open-label Phase II | 42 patients | 3 dosing arms.
📉 At Week 16 (MRI tumor-volume reduction):
- 1.2 mg daily: 51.91%
- 2 mg intermittent: 15.25%
- 4 mg intermittent: 9.50%
📊 RECIST response: 35.7% vs 21.4% vs 21.4%.
⏳ With longer follow-up on daily treatment:
- 85.88% median best tumor-volume reduction — approximately 86% shrinkage!
- 57.1% confirmed response rate (24/42 patients).
⚠️ Safety: Ovarian toxicity in 52.2% of women of childbearing potential during the randomized phase.
✅ Take-home: Continuous daily dosing showed promising, deeper tumor shrinkage and was selected for Phase III. Larger confirmatory evidence is awaited.
📚 Reference: Chugh et al. J Clin Oncol. 2026;44:3151–3162. DOI: 10.1200/JCO-26-00725.
#RINGSIDE #Varegacestat #DesmoidTumor #JCO2026 #Oncology #ClinicalTrials #MVOnco
@OncoDaily @OncoAlert @larvol
Willem Lybaert retweeted
Un angolo affascinante di #Roma 🤍
Un trafficato incrocio stradale, che un tempo era il Foro Boario…
L'antico mercato del bestiame di Roma,
con uno scorcio del Tempio di Ercole Vincitore
Willem Lybaert retweeted
📣 Supporting #NETPRACTICE, an international initiative led by @Alej_GarciaMD @VHIO 🌍
🔬 Do you treat patients with #NETs? Share your clinical experience and unmet needs!
🌎 70 responses | 12 countries
⏱️ 12–15 min | 🔒 Anonymous
📊 First results at #ENETS
🔗 docs.google.com/forms/d/e/1F…
@Alej_GarciaMD @JHernando3 @Ja_Capdevila @VHIO @GrupoGetne
Willem Lybaert retweeted
For patients with resectable locally advanced #HeadAndNeckSquamousCellCarcinoma, perioperative camrelizumab plus chemotherapy improved 2-year event-free survival vs standard surgery-based treatment. ja.ma/4kaMIR0
Willem Lybaert retweeted
START NUTRITION EARLY — DON'T WAIT FOR WEIGHT LOSS!
JAMA Oncology 2026 | Nasopharyngeal Carcinoma
🔹 RCT: 216 patients receiving concurrent chemoradiotherapy (CCRT).
🔹 Comparison:
- Early ONS (n=107): Started with CCRT.
- Routine ONS (n=109): Started after nutritional decline.
🔹 >5% Weight Loss: 65.4% vs 80.7%
RR 0.81 | P=.01 — 19% relative risk reduction!
🔹 Severe mucositis: 14.0% vs 26.6% (exploratory).
✅ Takeaway: Start nutritional support early, but remember that significant weight loss remains common despite intervention.
📖 Su et al. JAMA Oncol. 2026. DOI: 10.1001/jamaoncol.2026.4535
#JAMAOncology #NPC #NutritionSupport #Oncology #MVOnco @OncoDaily @OncoAlert @larvol
Willem Lybaert retweeted
🌍 NCCN Colon Cancer v3.2026 (JNCCN Guidelines Insights)
The clinical changes now in force came in Versions 1.2026 and 2.2026. The biggest are:
💊 Aspirin for tumors with somatic PI3K pathway alterations
✅ Atezolizumab + FOLFOX/CAPEOX: preferred adjuvant option in stage III dMMR (ATOMIC, DFS HR 0.50) - although I still think we don't need folfox here.
✅Neoadjuvant immunotherapy for dMMR T4 or bulky tumors
✅Thermal ablation for small liver metastases
✅ Encorafenib + anti-EGFR + FOLFOX or FOLFIRI: preferred 1L in BRAF V600E mCRC (BREAKWATER, OS HR 0.49)
🧬 Pretreatment DPYD testing, after the FDA label change for capecitabine and 5-FU
#CRC #ColonCancer #NCCN #DPYD #GIOnc
jnccn.org/view/journals/jncc…
Willem Lybaert retweeted
HexAgon-HN | ESMO 2026 | LBA42
Can activating T cells AND releasing their brakes improve first-line immunotherapy in head & neck cancer?
HexAgon-HN explores a dual immunotherapy strategy in recurrent/metastatic HNSCC with PD-L1 CPS ≥20.
🧬 The mechanism
- INBRX-106 (OX40 agonist): Stimulates T-cell activation and expansion.
- Pembrolizumab (PD-1 inhibitor): Releases inhibitory signalling on T cells.
- Together → Potentially stronger antitumour immunity.
📊 Key Phase II findings
- Confirmed ORR: 48.3% vs 26.5%
- Median PFS: 9.6 vs 4.9 months (interim)
- Complete responses: 13.8% vs 0%
- HPV-positive subgroup ORR: 80% vs 33.3% (n=10 vs 9)
⚠️ What should we remember?
Encouraging response rates and preliminary PFS, but the HPV-positive subgroup is very small, OS benefit remains unproven, and Phase III validation is essential.
Promising biology. Encouraging efficacy. Not yet practice-changing.
#ESMO2026 #HexAgonHN #HNSCC #Immunotherapy #OX40 #Pembrolizumab #HeadAndNeckCancer #MVOnco
@myESMO @OncoAlert @OncoDaily @larvol
Willem Lybaert retweeted
📢 One day left to submit your abstract for #ENETS2027!
Share your research in Milan and connect with the international neuroendocrine tumour community.
🔔 Deadline: 5 November, 23:59 CET
Submit your abstract now:
enetsconference.org/abstract…
🤖 Made with AI
Willem Lybaert retweeted
Thanks for sharing!
Daraxonrasib plus chemo ORR 59%, daraxonsrasib plus vopimetostat ORR 82%.
So systemic treatment of pancreatic cancer is evolving, I am sure that we will more discuss and see in near future cases as oligometastatic, curative intent, conversion, total neoadjuvant etc in pancreatic cancer!
Willem Lybaert retweeted
What do the results of the QoLATI/DAHANCA34 trial suggest about QoL after TORS vs IMRT in early-stage #OropharyngealCancer? 🤔
Find out from Hani Channir, who explored the results with us at #ESMO26 📊
👉: ow.ly/qFi551034a2
#Oncology #hncSM #TrialUpdate #RadOnc @myESMO
Intended for healthcare professionals
Willem Lybaert retweeted
🦄 UNICORN | Nature Medicine 2026
Can we break immunotherapy resistance in pMMR colon cancer?
Short-course botensilimab + balstilimab showed promising pathological responses:
🔹 pMMR: 36% pMR | 29% pCR
🔹 dMMR: 100% pMR | 93% pCR
🔹 ctDNA: All 5 pMMR major responders achieved clearance.
A promising step toward overcoming ICI resistance — Phase III confirmation awaited.
#UNICORN #ColonCancer #Immunotherapy @OncoAlert @OncoDaily @larvol
Willem Lybaert retweeted
Annoiato looks close enough to “annoyed” to fool you. But it describes a different feeling.
Sono annoiato. = I’m bored.
Sono infastidito. = I’m annoyed.
Picture two moments. In one, you have nothing interesting to do. In the other, a phone keeps ringing while you’re trying to concentrate.
The first fits annoiato. The second fits infastidito.
These examples use masculine singular endings. A woman describing herself would say:
Sono annoiata.
Sono infastidita.
The meaning stays the same; the adjective ending changes to match the person.
A useful memory link: noia means “boredom.” It helps you connect annoiato to being bored instead of trusting its resemblance to an English word.
Quick check: someone says “Sono annoiato.” Are they asking you to stop doing something irritating? Not necessarily. They’re telling you they’re bored. Suggesting an activity would make more sense than assuming you’ve upset them.
Practice expressing what you actually mean with ItalianChat. Free to try for 3 days:
learnitalianpod.com/italianc…






























